New use of n-alkanols as activators of the CFTR channel (cystic fibrosis transmembrane conductance regulator) and application of said use to the treatment of pathologies in which a dysfunction of said channel is observed, such as cystic fibrosis.Nouvelle utilisation des n-alkanols comme activateurs du canal CFTR (cysticfibrosis transmembrane conductance regulator) et application de laditeutilisation aux traitements des pathologies dans lesquelles on observe undysfonctionnement dudit canal, telles que la mucoviscidose.